MPS Invests $16.5 Million in Unbound Medicine Through Mixed Debt-Equity Structure

MPS has announced a strategic investment of $16.5 million in Unbound Medicine, marking a significant expansion move in the North American healthcare technology market. The investment utilizes a mixed debt and equity financing structure, demonstrating the company's flexible approach to strategic partnerships. Investment Structure and Strategic Approach The $16.5 million investment combines both debt and equity components, providing MPS with a balanced financial structure for this strategic partnership. This mixed financing approach allows for optimal capital deployment while maintaining strategic flexibility in the partnership with Unbound Medicine. Investment Details: Specifications Total Investment: $16.5 million Financing Structure: Mixed debt and equity Target Market: North America Focus Area: Healthcare technology growth Growth Objectives in North America The investment is specifically designed to fuel growth initiatives for Unbound Medicine in the North American market. This strategic move positions MPS to capitalize on expanding opportunities in the healthcare technology sector, leveraging Unbound Medicine's market presence and capabilities. Strategic Implications This investment represents MPS's commitment to strengthening its foothold in the North American healthcare technology landscape. The mixed debt-equity structure provides both companies with the financial flexibility needed to pursue aggressive growth strategies while maintaining operational independence. The partnership is expected to enhance both companies' competitive positioning in the rapidly evolving healthcare technology market. MPS Pharmaa Limited has published its unaudited financial results for the third quarter and nine months ended December 31, 2025, revealing continued operational challenges with widening losses across all reporting periods. Financial Performance Overview The pharmaceutical company reported deteriorating financial performance across key metrics for Q3FY26. The company's financial results demonstrate persistent operational difficulties with no revenue generation from core business activities. Metric Q3FY26 Nine Months FY26 Q3FY25 Total Income from Operations - - ₹4.38 lakh Net Loss Before Tax ₹22.95 lakh ₹68.83 lakh ₹17.79 lakh Net Loss After Tax ₹22.03 lakh ₹66.06 lakh ₹17.46 lakh Total Comprehensive Income ₹21.78 lakh loss ₹65.32 lakh loss ₹17.25 lakh loss Earnings Per Share Analysis The company's earnings per share metrics reflected the ongoing losses, with both basic and diluted EPS remaining in negative territory. For the quarter ended December 31, 2025, both basic and diluted EPS stood at negative ₹0.12, compared to negative ₹0.09 in the corresponding quarter of the previous year. For the nine-month period, the EPS deteriorated further to negative ₹0.35 for both basic and diluted calculations, indicating the cumulative impact of sustained losses on shareholder value. Capital Structure The company maintained its equity share capital at ₹1,911.14 lakh throughout the reporting periods, with no changes in the capital structure. The face value of equity shares remains at ₹10 each. Operational Challenges A significant concern highlighted in the results is the complete absence of operational income during both the current quarter and nine-month period ended December 31, 2025. This contrasts with the previous year's Q3FY25, when the company recorded operational income of ₹4.38 lakh. Regulatory Compliance MPS Pharmaa Limited, formerly known as Advvik Laboratories Limited, submitted the financial results in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company published the results in Financial Express (English) and Jansatta (Hindi) newspapers on February 3, 2026. The complete financial results are available on stock exchange websites including BSE ( www.bseindia.com ) and ASE ( www.aselindia.co.in ), as well as on the company's website www.mpspharmaa.com . The results were signed by Chairman Peevush Kumar Aggarwal (DIN: 00090423) on February 2, 2026. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.